Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT. (2016)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/bmt.2016.19
PubMed Identifier: 26901708
Publication URI: http://europepmc.org/abstract/MED/26901708
Type: Journal Article/Review
Volume: 51
Parent Publication: Bone marrow transplantation
Issue: 6
ISSN: 0268-3369